Carroll Investors’s DexCom DXCM Stock Holding History

Carroll Investors’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-104	Closed	-$13K	–	63
2022 Q1	$13K	Sell	104 -508	-83%	-$55.6K	0.01%	120
2021 Q4	$80K	Buy	+612	New	+$87.9K	0.05%	72

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Carroll Investors's DXCM Position: Q2 2022 in Review

Carroll Investors sold out of DexCom (DXCM) in Q2 2022, closing a stake of 104 shares — an estimated $13K sold.

Carroll Investors first reported a position in DXCM in Q4 2021 and held it in 2 quarters. The position peaked at $80K in Q4 2021. 797 funds tracked by Wall St. Rank hold DXCM as of Q2 2022.

Carroll Investors reported no remaining DexCom position as of Q2 2022 after selling out during the quarter.
Carroll Investors sold 104 DexCom shares in Q2 2022, an estimated $13K.
Carroll Investors first reported a position in DexCom in Q4 2021 and held it in 2 quarters.
Carroll Investors's DexCom position peaked at $80K in Q4 2021.
797 funds tracked by Wall St. Rank held DexCom as of Q2 2022.

Based on Carroll Investors's 13F filing for Q2 2022, filed 26 Jul 2022.